Janux Therapeutics (JANX) Accumulated Expenses: 2020-2025
Historic Accumulated Expenses for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $22.2 million.
- Janux Therapeutics' Accumulated Expenses rose 70.14% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 70.14%. This contributed to the annual value of $11.7 million for FY2024, which is 58.17% up from last year.
- Janux Therapeutics' Accumulated Expenses amounted to $22.2 million in Q3 2025, which was up 38.22% from $16.0 million recorded in Q2 2025.
- Over the past 5 years, Janux Therapeutics' Accumulated Expenses peaked at $22.2 million during Q3 2025, and registered a low of $2.0 million during Q3 2021.
- For the 3-year period, Janux Therapeutics' Accumulated Expenses averaged around $11.1 million, with its median value being $9.2 million (2023).
- Per our database at Business Quant, Janux Therapeutics' Accumulated Expenses surged by 403.20% in 2021 and then declined by 24.91% in 2024.
- Over the past 5 years, Janux Therapeutics' Accumulated Expenses (Quarterly) stood at $3.8 million in 2021, then surged by 116.43% to $8.2 million in 2022, then decreased by 9.68% to $7.4 million in 2023, then soared by 58.17% to $11.7 million in 2024, then spiked by 70.14% to $22.2 million in 2025.
- Its Accumulated Expenses was $22.2 million in Q3 2025, compared to $16.0 million in Q2 2025 and $13.3 million in Q1 2025.